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doi:10.1016/j.jmii.2011.09.001Background and purpose: Amino acid substitutions in GyrA and ParC are associated with resis-
tance to quinolones in Acinetobacter baumannii (A baumannii), but this association is rarely
elucidated in Acinetobacter genomic species (AGS) 13TU. This study aims to compare the asso-
ciation of amino acid substitutions in GyrA and ParC with quinolone resistance in A baumannii
and AGS 13TU in Taiwan.
Methods: Eleven representative strains of A baumannii and 13 strains of AGS 13TU were
selected from 402 bacteremic isolates. The sequences of quinolone resistance determining
regions of gyrA and parC were determined. Minimal inhibitory concentrations (MICs) of nali-
dixic acid, ciprofloxacin, levofloxacin and moxifloxacin were determined by agar dilution
method.
Results: Ser83Leu substitution in GyrA in A baumannii (one strain) was associated with resis-
tance to all tested quinolones. This substitution plus a Ser80Leu or Ser80Tyr in ParC in A bau-
mannii (four strains) and AGS 13TU (two strains) were associated with higher MICs of all
quinolones. All but one quinolone MICs of A baumannii (one strain) and AGS 13TU (two strains)
carrying a single substitution Ser56Asn in ParC remained in the susceptibility breakpoint. Thefectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Number 201, Section 2,
om (T.-L. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Amino acid substitutions in GyrA and Parc of Acinetobacter 109Ser83Leu substitution in GyrA, even with additional Ser56Asn substitution in ParC, was associ-
ated with resistance to only nalidixic acid, but not other newer quinolones in AGS 13TU (two
strains).
Conclusion: A baumannii and AGS 13TU possessed similar quinolone resistance associated with
amino acid substitutions in GyrA and ParC. Further study with more strains is needed to deter-
mine whether a single Ser83Leu substitution in GyrA was associated with a high level of quino-
lone MIC only in A baumannii, but not in AGS 13TU.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acinetobacter species, especially A baumannii, Acineto-
bacter genomic species (AGS) 3 and 13TU, have emerged as
important pathogens of nosocomial infection with high
mortality and morbidity in critically ill patients.1,2 They
also cause outbreaks in intensive care units and are difficult
to eradicate because of their ability to survive in harsh
environments for a prolonged time.3 With their ability to
accumulate different mechanisms of resistance and
increasing numbers of more vulnerable hosts, the preva-
lence of multidrug resistant Acinetobacter spp. has been
rising in the past decades and the choice of treatment has
become limited.4,5 Although they are phenotypically
undifferentiated, they have distinct resistance mechanisms
for antimicrobial agents. As for resistance to aminoglyco-
sides, A baumannii carries armA and aph(30)-Ia, whereas
AGS 13TU possesses aac(3)-Ia and aph(30)-VI.6 For resistance
to carbapenems, blaIMP-1 and blaVIM-11, which belong to
class B metallo-beta-lactamase genes, are more commonly
found in AGS 13TU, and the class D carbapenemase genes
are observed more often in A baumannii.7 Quinolones have
been used for the treatment of Acinetobacter spp. because
of their good activity, even compared with broad-spectrum
cephalosporins and aminoglycosides, until a high rate of
resistance to quinolones was detected recently.8e10 Three
mechanisms of resistance to quinolones have been recog-
nized: (1) mutations in target enzymes; (2) changes in drug
entry and efflux; and (3) plasmid-mediated Qnr protein,
which prevents DNA from quinolone binding and compro-
mises the efficacy of quinolones.11e13 The most commonly
identified mechanism in Gram-negative bacilli is mutations
in target enzymes including DNA gyrase, encoded by gyrA
and gyrB, and topoisomerase IV, encoded by parC and parE.
In A baumannii, rapid resistance to ciprofloxacin and nali-
dixic acid is associated with the chromosomal mutations in
the quinolone resistance determining regions (QRDRs) of
gyrA and/or parC.4,5,8,9,14 Single amino acid substitution in
GyrA (Ser83Leu) is associated with high level resistance to
ciprofloxacin and nalidixic acid.4,5,9 An additional amino
acid substitution in ParC, mostly Ser80Leu, is associated
with higher resistance in A baumannii.8,9,14 To date, the
majority of the data regarding quinolone resistance focused
on A baumannii.4,5,8,9,14 In contrast, the mechanism of
quinolone resistance in AGS 13TU, which is genetically
closely related to and phenotypically undifferentiated from
A baumannii,3 is not elucidated. Recent studies showed
that A baumannii and AGS 13TU possess remarkably distinct
phenotypic and genotypic traits against antimicrobialagents.15,16 Lee et al reported A baumannii bacteremia was
associated with a higher 14-day mortality rate, a higher 30-
day mortality rate and a higher in-hospital mortality rate
than bacteremia due to AGS 13TU or 3.17 Chuang et al
revealed higher rates of antimicrobial resistance and
poorer outcome for patients infected with A baumannii
than for those infected with AGS 13TU or 3.18 The preva-
lence of resistance to ciprofloxacin was different in these
studies, but the mechanism was not analyzed. The major
aim of the present study was to compare the association of
amino acid substitutions in GyrA and ParC with quinolone
resistance between the clinical isolates of A baumannii and
AGS 13TU in Taiwan.
Materials and methods
Bacterial strains and antimicrobial susceptibility
testing
During 2006 and 2008, 402 bacteremic isolates of Acineto-
bacter spp. were collected. Twenty-four representative
strains of Acinetobacter spp. with different susceptibility to
quinolones and pulsotypes were selected for the study. All
strains had been identified to the genomic species level by
eitheramultiplexPCRmethod19or sequencinganalysisof16S-
23S rRNA internal transcribed spacer.20 Susceptibility against
nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin
were established by the agar dilution method recommended
by the Clinical and Laboratory Standards Institute (CLSI).21
The breakpoints proposed by CLSI were used for nalidixic
acid (susceptible  16 mg/mL; resistant  32 mg/mL),22
ciprofloxacin (susceptible  1 mg/mL; resistant  4 mg/mL)
and levofloxacin (susceptible  2 mg/mL; resistant  8 mg/
mL).21 The breakpoint of moxifloxacin (susceptible  1 mg/
mL; resistant 4 mg/mL) was proposed by the manufacturer.
Amplification and DNA sequencing of the QRDRs
of the gyrA and parC
The QRDRs of gyrA and parC were amplified with the
following primer pairs: 50-atgagcgtatcggaaatccg-30 and
50-ggtatttaccacgaatgtgtaa-30 for gyrA, and 50-atgaccagcctt
gcgcatc-30 and 50-gttatcttgccattcgctagt-30 for parC with
a proof-reading polymerase (Takara Bio Inc, Otsu, Shiga,
Japan), yielding amplicons of 733 and 450 base pairs,
respectively. Polymerase chain reaction (PCR) program
was as follows: 94C for 1 minute, 35 cycles at 98C for
10 seconds, and 60C for 1 minute with a final extension at
110 Y.-H. Liu et al.72C for 10 minutes. The amplified DNA product was
resolved by electrophoresis in agarose 2% w/v gels, stained
with ethidium bromide, and purified according to the
manufacturer’s instruction (Geneaid Biotech Ltd, Taipei,
Taiwan). The purified PCR product was cloned into a pCRII-
TOPO vector and transformed into Escherichia coli (Invi-
trogen Corp., Carlsbad, CA, USA). The sample was then
processed for DNA sequencing (Mission Biotech, Taipei,
Taiwan).
Results
A total of 24 representative strains comprising A baumannii
(11 strains) and AGS 13TU (13 strains) were included in the
study. The amino acid substitutions in the QRDRs of the
GyrA and ParC of these strains and their association with
quinolone MICs were presented.
For A baumannii, five strains (strain number 16, 129,
202, 312, 305) had mutation on QRDRs of gyrA, leading to an
amino acid Ser83Leu substitution (Table 1). A strain with
only the single Ser83Leu substitution in GyrA displayed
resistance to all tested quinolones. Among these five
strains, four strains (strain number 129, 202, 312, 305) had
simultaneous Ser80Leu or Ser80Tyr substitutions in ParC.
These four strains had higher level of quinolone MICs,
compared to those with only Ser83Leu in gyrA. Strain
number 514 had a single Ser56Asn substitution in ParC, but
the MICs of all quinolones tested were similar to those
without the amino acid substitution.
For AGS 13TU, four strains (number 242, 254, 405, 454)
had mutations on QRDRs of the gyrA gene, resulting in an
amino acid Ser83Leu substitution (Table 2). Six strains
(number 23, 242, 254, 405, 454, 502) had either ParC 56
(Ser56Asn) or ParC 80 (Ser80Leu) amino acid substitution.
The two strains (405 and 454) with simultaneous substitu-
tions in GyrA 83 and ParC 80 displayed the highest level of
quinolone MICs. For the two strains (number 242 and 254)
that carried the simultaneous substitutions in GyrA 83 and
ParC 56, the MICs of nalidixic acid were still high, but MICs
of ciprofloxacin, levofloxacin and moxifloxacin were within
susceptibility or just intermediate breakpoint. For the two
strains (number 502 and 23) with just a single substitutionTable 1 Minimal inhibitory concentrations (MICs) of quinolone
mining regions of GyrA and ParC in Acinetobacter baumannii
Strains MIC(mg/mL)
Nalidixic acid Ciprofloxacin Levofloxacin
514 8 0.25 0.25
5 8 0.25 0.25
294 8 0.5 0.25
24 8 1 0.5
15 16 0.5 1
25 16 1 0.5
16 >64 16 8
129 >64 64 16
202 >64 >64 16
312 >64 >64 16
305 >64 >64 16Ser56Asn in ParC, strain number 502 did not have significant
MIC change, compared with the strains without any amino
acid substitution in the QRDRs of both GyrA and ParC. For
strain number 23, the MIC of nalidixic acid was slightly
higher than that found in strains without any amino acid
substitution, but the MICs of ciprofloxacin, levofloxacin and
moxifloxacin were similar to those of strains 242 and 254,
which simultaneously had amino acid substitutions in GyrA
83 and ParC 56.
Discussion
Among Acinetobacter spp., A baumannii and AGS 13TU are
the most clinically relevant pathogens of nosocomial infec-
tions.23 They have different clinical features, outcomes
and resistance rates to several antibiotics,17 including
fluoroquinolones. In Sheng’s study,24 as compared with
carbapenem-resistant A baumannii, carbapenem-resistant
AGS 13TU and 3 isolates have higher antimicrobial suscep-
tible rates to ciprofloxacin. It is well-known that, for resis-
tance to quinolones, amino acid substitutions in GyrA and
ParC play important roles in Gram-negative bacilli.25 The
contribution of amino acid substitutions in GyrA and ParC to
quinolone resistance may be unequal among different
Gram-negative bacilli. In Pseudomonas aeruginosa, the flu-
oroquinolone resistance is mainly due to gyrA mutations,
with parC mutations being less significant.26 Double muta-
tions in gyrA and parC were needed for high level resistance
to quinolones in A baumannii, but three or four mutations in
both gyrA and parC genes are required for high-level resis-
tance to ciprofloxacin in E coli.8,27,28 Therefore, our study
compared the association of amino acid substitutions in
GyrA and ParC with quinolone resistance in the two most
clinically important Acinetobacter spp., A baumannii and
AGS 13TU.
Our study revealed that the association of amino acid
substitutions of GyrA and ParC with quinolone resistance in
A baumannii and AGS 13TU was largely similar, with only
a mild discrepancy. Single amino acid Ser83Leu substitution
in GyrA was associated with high level MICs of all quinolones
in A baumannii, but only associated with a high level of MIC
of nalidixic acid in AGS 13TU. Further substitution in ParCs and amino acid substitution in quinolone resistance deter-
Amino acid substitution
Moxifloxacin GyrA Ser83 ParC Ser56 ParC Ser80
0.125 Ser Asn Ser
0.125 Ser Ser Ser
0.25 Ser Ser Ser
0.5 Ser Ser Ser
0.25 Ser Ser Ser
0.5 Ser Ser Ser
8 Leu Ser Ser
16 Leu Ser Tyr
32 Leu Ser Leu
32 Leu Ser Leu
32 Leu Ser Leu
Table 2 Minimal inhibitory concentrations (MICs) of quinolones and amino acid substitution in quinolone resistance deter-
mining regions of GyrA and ParC in Acinetobacter genomic species 13TU
Strains MIC(mg/mL) Amino acid substitution
Nalidixic acid Ciprofloxacin Levofloxacin Moxifloxacin GyrA Ser83 ParC Ser56 ParC Ser80
20 4 0.25 0.125 0.125 Ser Ser Ser
500 4 0.125 0.125 <0.125 Ser Ser Ser
502 4 0.125 0.125 <0.125 Ser Asn Ser
12 8 0.25 0.25 0.125 Ser Ser Ser
27 8 0.25 0.25 0.125 Ser Ser Ser
316 8 2 1 1 Ser Ser Ser
356 16 0.5 0.5 0.5 Ser Ser Ser
13 16 1 0.5 0.125 Ser Ser Ser
23 16 4 1 1 Ser Asn Ser
242 >64 2 1 2 Leu Asn Ser
254 >64 2 1 1 Leu Asn Ser
405 >64 >64 >32 32 Leu Ser Leu
454 >64 >64 >32 16 Leu Ser Leu
Amino acid substitutions in GyrA and Parc of Acinetobacter 11180, which combined the occurrence of the substitution in
GyrA 83, achieved a higher level of MICs of all the quino-
lones in both Acinetobacter species (Tables 1 and 2). These
mechanisms resembled those in other Gram-negative
bacilli.8,9,14 This study also demonstrated that newer fluo-
roquinolones were less influenced by amino acid substitu-
tions in GyrA and ParC in Acinetobacter.14, 29 This may be
partially explained by the intrinsic structure of different
quinolones.12,30e32 Unexpectedly, with s similar Ser83Leu
substitution in GyrA, A baumannii became more resistant
than AGS 13TU to newer fluoroquinolones. If this result can
be demonstrated in more strains, it may be one of the
reasons to explain the higher rate of resistance to quino-
lones in A baumannii than AGS 13TU.
To the best of our knowledge, a novel substitution in
ParC 56 was found in Acinetobacter in the current study.
Substitutions of ParC at Ser80 and Glu84 have been previ-
ously detected and contribute to MIC change in A. bau-
mannii. Chiu et al33 observed a novel parC gene mutation
leading to amino acid substitution, Lys59Gln. In the
absence of concurrent amino acid substitution in GyrA, the
Lys59Gln in ParC was associated with ciprofloxacin resis-
tance. The result disclosed that in A baumannii substitution
of ParC might be as important as substitution of GyrA.
However, a high level of expression of AdeB, an efflux pump
protein, was found in the resistant strain. Thus, the author
suggested that ParC Lys59Gln mutation and the efflux pump
may function synergistically to induce resistance to cipro-
floxacin. In our study, substitution in ParC, without substi-
tution in GyrA, were noted both in A baumannii and AGS
13TU. Although the substitution was not associated with
significant MIC change in strain 514 of A baumannii and
strain 502 of AGS 13TU, the MICs of nalidixic acid and
ciprofloxacin in strain 23 of AGS 13TU increased (MIC of
16 mg/mL for nalidixic acid and 4 mg/mL for ciprofloxacin).
It implied that in AGS 13TU, ParC may be more than
a secondary target, although the synergistic role should
also be considered.
In conclusion, A baumannii and AGS 13TU possess similar
substitutions in QRDRs in GyrA and ParC that are associated
with quinolone resistance. Single substitution Ser83Leu atGyrA could confer high level resistance to quinolones in
A baumannii, but may not confer high level resistance to
newer fluoroquinolones in AGS 13TU. An additional substi-
tution at ParC 80 was associated with a higher level of
resistance to quinolones in both Acinetobacter spp. The
role of substitution at ParC 56 needs to be further
elucidated.References
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